Development of NK3R Antagonists with a Labile Functional Group in the Natural Environment

Part of the Springer Theses book series (Springer Theses)


For development of novel NK3R antagonists with reduced environmental toxicity, a structure-activity relationship study of an NK3R antagonist, talnetant, was conducted. Among several talnetant derivatives with labile functional groups in the natural environment, a 3-mercaptoquinoline derivative exhibited comparable biological activity to that of the parent talnetant. Additionally, 3-mercaptoquinoline was converted into the disulfide or isothiazolone form by air-oxidation, both of which showed no binding affinity to NK3R.


NK3R antagonist Talnetant Air-oxidation 


  1. 1.
    (a) Giardina GAM, Sarau HM, Farina C, Medhurst AD, Grugni M, Raveglia LF, Schmidt DB, Rigolio R, Luttmann M, Vecchietti V, Hay DWP (1997) Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 1. Identification of the 4-quinolinecarboxamide framework. J Med Chem 3:1794–1807. (b) Giardina GAM, Raveglia LF, Grugni M, Sarau HM, Farina C, Medhurst AD, Graziani D, Schmidt DB, Rigolio R, Luttmann M, Cavagnera S, Foley JJ, Vecchietti V, Hay DWP (1999) Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412). J Med Chem 42:1053–1065Google Scholar
  2. 2.
    (a) Dawson LA, Cato KJ, Scott C, Watson JM, Wood MD, Foxton R, de la Flor R, Jones GA, Kew JN, Cluderay JE, Southam E, Murkitt GS, Gartlon J, Pemberton DJ, Jones DN, Davies CH, Hagan J (2008) In Vitro and In Vivo Characterization of the Non-peptide NK3 Receptor Antagonist SB-223412 (Talnetant): Potential Therapeutic Utility in the Treatment of Schizophrenia. Neuropsychopharmacology 33:1642–1652. (b) de la Flor R, Dawson LA (2009) Augmentation of antipsychotic-induced neurochemical changes by the NK3 receptor antagonist talnetant (SB-223412). Neuropharmacology 56:342–349Google Scholar
  3. 3.
    (a) Fioramonti J, Gaultier E, Toulouse M, Sanger GJ, Bueno L (2003) Intestinal anti-nociceptive behaviour of NK3 receptor antagonism in conscious rats: evidence to support a peripheral mechanism of action. Neurogastroenterol Motil 15:363–369. (b) Bueno L (2005) Gastrointestinal pharmacology: irritable bowel syndrome. Curr Opin Pharmacol 5:583–588Google Scholar
  4. 4.
    Newton CL, Anderson C, Millar P (2016) Therapeutic Neuroendocrine agonist and antagonist analogs of hypothalamic neuropeptides as modulators of the hypothalamic-pituitary-gonadal axis. Adv Ther Pediatr Endocrinol Diabetol 30:106–129Google Scholar
  5. 5.
    Geldenhuys WJ, Kuzenko SR, Simmons MA (2010) Virtual screening to identify novel antagonists for the G protein-coupled NK3 receptor. J Med Chem 53:8080–8088Google Scholar
  6. 6.
    Labaw CS, Liu P (2007) Method for the synthesis of quinoliνe derivatives. PCT international application WO 2007/016609 A2Google Scholar
  7. 7.
    Misu R, Oishi S, Yamada A, Yamamura T, Matsuda F, Yamamoto K, Noguchi T, Ohno H, Okamura H, Ohkura S, Fujii N (2014) Development of novel neurokinin 3 receptor (NK3R) selective agonists with resistance to proteolytic degradation. J Med Chem 57:8646–8651Google Scholar
  8. 8.
    Xiong H, Kang J, Woods JM, McCauley JP, Koether GM, Albert JS, Hinkley L, Li Y, Gadient RA, Simpson TR (2011) Synthesis and SAR of sulfoxide substituted carboxyquinolines as NK3 receptor antagonists. Bioorg Med Chem Lett 21:1896–1899Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  1. 1.Graduate School of Pharmaceutical SciencesKyoto UniversityKyotoJapan

Personalised recommendations